Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.35 |
| ▸ | CCND1 | P24385 | 5/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
| ▸ | PRKACB | P22694 | 1/20 | 0.35 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6327416 | 0.87 | GSK3B (0.33) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6327468 | 0.81 | CDK4 (0.35) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6328003 | 0.76 | GSK3B (0.49) | CDK4CCND1CAMK2D | |
| SCHEMBL6328457 | 0.73 | CDK4 (0.46) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL1395909 | 0.72 | CDK4 (0.44) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6806997 | 0.70 | GSK3B (0.46) | CDK4CAMK2D | |
| SCHEMBL6799178 | 0.70 | GSK3B (0.42) | CDK4CAMK2D | |
| SCHEMBL6802576 | 0.70 | GSK3B (0.37) | CDK4CCND1CAMK2D | |
| SCHEMBL6801058 | 0.69 | GSK3B (0.43) | CDK4CAMK2D | |
| SCHEMBL6803328 | 0.69 | GSK3B (0.41) | CDK4CAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | CDK4 5/4885CCND1 70/4885PRKACA 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.